Medicaid's β 2 -Agonist Recipients and Their Treatment by National Standards

Abstract

Spanish

French

OBJECTIVE:

To determine whether Connecticut's Medicaid high-dose β₂-agonists (HDB) users (>1 canister/mo) are receiving medications according to National Institutes of Health (NIH) asthma guidelines, and to compare healthcare utilization between HDB users and patients receiving no more than one canister of a short-acting β₂-agonist per month.

METHODS:

All Connecticut Medicaid pharmacy claims from April to December 1998 were examined. Subjects were included if they had an asthma diagnosis and were excluded if they had chronic obstructive pulmonary disease. The percentage of HDB users not receiving long-term-control medication; receiving low doses of a long-term-control medication; and receiving oral, nebulized, or long-acting β₂-agonists was determined. Healthcare utilization between HDB users and patients receiving no more than one canister of a short-acting β₂-agonist per month was also compared.

RESULTS:

Of 1599 profiles included, 14% (n = 223) were HDB users. Twenty-five percent of these patients did not receive a long-term-control medication, and 35% received low doses of a long-term-control medication. Claims for oral, nebulized, and long-acting β₂-agonists were submitted for 4%, 29%, and 22% of HDB users, respectively. More claims for short courses of oral corticosteroids were submitted for HDB users than for patients receiving no more than one canister of a short-acting β₂-agonist per month (n = 1376) (1.99 ± 3.60 vs. 0.39 ± 1.07 mean ± SD; p < 0.001). HDB users visited their physicians' offices an average of 4.72 ± 24.08 × per month compared with an average of 2.40 ± 14.4 office visits per month for patients receiving no more than one canister of a short-acting β₂-agonist (p = 0.04).

CONCLUSIONS:

A high proportion of Connecticut's Medicaid HDB users are not receiving medications according to NIH guidelines. HDB users were significantly more likely to receive short courses of oral corticosteroids and required significantly more office visits than patients receiving no more than one canister of a short-acting β₂-agonist per month. Intervention programs designed to improve adherence to the guidelines will be developed.

Keywords

asthma Medicaid

Get full access to this article

View all access options for this article.

References

Hartert

Peebles

. Epidemiology of asthma: The year in review. Curr Opin Pulm Med 2000;6(1):4–9.

Expert Panel Report II: Guidelines for diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Lung Blood Institute, 1997.

Weiss

Sullivan

. The health economics of asthma and rhinitis. I. Assessing the economic impact. J Allergy Clin Immunol 2001;107:3–8.

MacKinnon

Flagstad

Peterson

Mesch-Beatty

. Disease management program for asthma: Baseline assessment of resource use. Am J Health Syst Pharm 1996;53:535–41.

Suissa

Blais

Ernst

. Patterns of increasing β-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994;7:1602–9.

Stempel

Durcannin-Robbins

Hedblom

Woolf

Sturm

Stempel

. Drug utilization evaluation identifies costs associated with high use of beta-adrenergic agonists. Ann Allergy Asthma Immunol 1996;76:153–8.

Diette

Skinner

Markson

Clark

McDonald

Treatment patterns associated among adult patients with asthma: Factors associated with overuse of inhaled beta-agonists and underuse of inhaled corticosteroids. Arch Intern Med 1999;159:2697–704.

Nestor

Calhoun

Dickson

Kalik

. Cross-sectional analysis of the relationship between national guideline recommended asthma drug therapy and emergency/hospital use within a managed care population. Ann Allergy Asthma Immunol 1998;81:327–30.

Legoretta

Christian-Herman

O'Connor

Hasan

Evans

Leung

. Compliance with national asthma management guidelines and specialty care: A health maintenance organization experience. Arch Intern Med 1998;158:457–64.

10.

Laumann

Bjornson

. Treatment of Medicaid patients with asthma: Comparison with treatment guidelines using disease-based drug utilization review methodology. Ann Pharmacother 1998;32:1290–4.

11.

Davidson

Klein

Settipane

Alario

. Access to care among children visiting the emergency room with acute exacerbations of asthma. Ann Allergy Asthma Immunol 1994;72:469–73.

12.

International Classification of Diseases. 9th rev. − 1998 hospital edition. Vols 1, 2, 3, 5th ed. Los Angeles: Practice Management Information Corporation,1997.

13.

Motheral

Fairman

. The use of claims databases for outcomes research: Rationale, challenges and strategies. Clin Ther 1997;19:346–66.

14.

Arnold

Kotsanos

Motheral

Ramsey

Crown

Puder

Panel 3: Methodological issues in conducting pharmacoeconomic evaluations — Retrospective and claims database studies. Value in Health 1999;2(2):82–7.